Oncology

The study evaluated carfilzomib in combination with Celgene's lenalidomide and dexamethasone.

ABT-414 is being developed to treat glioblastoma multiforme.

Today, the U.S. Food and Drug Administration took important steps to ensure that certain tests used by health care professionals to help diagnose and treat patients provide accurate, consistent and reliable results.

The study, published in the journal Cell, was conducted at the Whitehead Institute of Biomedical Research.

While Incyte and Genentech announced partnership to study each of their immunooncology molecules in NSCLC, AstraZeneca and Kyowa Hakko Kirin signed a similar agreement to evaluate their candidate molecules in multiple solid tumors.

Dr Koss refused preoperative chemotherapy to avoid damaging her virulent cells, which could later be cultured and could likely provide therapeutic leads.

The authors observed that an artificial switch in cancer cells from an epithelial to a mesenchymal phenotype induced the expression of GLUT3, a protein that promotes cellular glucose uptake.

Molecular analysis is now underway to characterize subsets of patients who performed better or worse on either treatment.

The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.

The drug is to be administered right before chemotherapy or radiation, to bind to and inhibit cell division in normal cells and reduce the adverse effects of chemotherapy.

AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

New trial data confirms its use as standard therapy for CLL.

HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.

Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.

Following the success of robotics in prostate surgeries, the technique was expected to provide comparable results for bladder cancer surgeries as well.

Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.

The approval is a big gain for melanoma (Yervoy) and prostate cancer (Xtandi) patients in England and Wales.

However, a point to note is that this was a small cohort study without a comparator arm.

The drug has been approved for use in patient's with relapsed disease.

According to a recent survey, radiation oncologists are doing this for 7.9% less pay than they earned the year before.

The researchers found that the risk of developing cervical cancer within three years following a negative HPV test result was about half of the already low risk following a negative Pap test.

Aduro joins the exclusive group of companies, so far only the big pharma, that have a successful trail of immunooncology candidates.